RBC Capital Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $5
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and lowers the price target from $7 to $5.
RBC Capital analyst Brian Abrahams maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and lowers the price target from $7 to $5.